FLT3 and acute myeloid leukemia: To ensure the reliability of this evaluation, we selected Quizartinib, a well-known second-generation FLT3 inhibitor approved by the FDA for treating relapsed or refractory AML with FLT3–ITD mutation, as the positive control [65].